Chemoimmunotherapy in urothelial cancer: concurrent or sequential?

Onkourologiâ

A. G. Dzidzariya¹  A. R. Vashurin¹  A. Yu. Pavlov¹  R. A. Gafanov¹  I. I. Khalil'¹ 

[1] Russian Scientific Center of Roentgen Radiology, Ministry of Health of Russia;

关键词: urothelial cancer;    immunochemotherapy;    immune checkpoint inhibitor;   

DOI  :  10.17650/1726-9776-2021-17-4-124-128

来源: DOAJ

【 摘 要 】

Advances in immuno-oncology in the treatment of metastatic urothelial cancer have overturned current perspectives on the treatment of this type of tumor. The success of using Immune checkpoint inhibitors in metastatic urothelial cancer raised the question of effectiveness of immunotherapy added to standard first-line chemotherapy. This review presents data coming from actual studies examining chemotherapy and immunotherapy in urothelial cancer, or a combination of these methods. Ongoing and planned clinical studies should help identify the optimal sequencing, feasibility of combination, and best duration of treatment with checkpoint inhibitors in urothelial cancer.

【 授权许可】

Unknown